Table 2.
The application of other cells derived EVs in cancer therapy.
| EVs type | EVs sources | Guest molecules | Target gene | Applications | Ref |
|---|---|---|---|---|---|
| sEVs | K562 cells | — | — | Induce anti-leukemic immunities | (Yao et al., 2014) |
| sEVs | Vδ2-T cells | — | — | Induce antitumor immunity | (Wang et al., 2020) |
| NVs | Autologous tumor | — | — | Inhibit melanoma growth and metastasis | (Lee et al., 2012) |
| sEVs | Tumor cells | — | — | Induce CD8+ T-cell-dependent antitumor effects | (Wolfers et al., 2001) |
| sEVs | Tumor cells | CpG DNA | — | For cancer immunotherapy | (Morishita et al., 2016) |
| sEVs | PEGylated Tumor cells | — | — | For cancer immunotherapy | (Ochyl et al., 2018) |
| sEVs | DC cells | — | — | Kill tumor and activate NK cells | (Munich et al., 2012) |
| sEVs | DC cells | — | — | Maintenance immunotherapy | (Besse et al., 2016) |
| sEVs | AFP express DC cells | — | — | For HCC immunotherapy | (Lu et al., 2017) |
| sEVs | DC cells | Fluorouracil | — | Enhance anti-colon cancer effect | (Xu et al., 2020) |
| NVs | M1 Macrophage | aPD-L1 | — | Potentiate aPD-L1 anticancer efficacy | (Choo et al., 2018) |
| EVs | M2 macrophage | miRNAs | — | Inhibit cell migration and invasion of gliomas | (Yao et al., 2021) |
| sEVs | NK cells | — | — | Target and therapy of glioblastoma | (Zhu et al., 2018) |
| sEVs | NK cells | — | — | Exert therapeutic effect in melanoma | (Zhu et al., 2017) |
| sEVs | NK cells | — | — | Antitumor activity of cytokine-activated NK cells | (Shoae-Hassani et al., 2017) |
| sEVs | NK cells | — | — | Maintain immune surveillance and homeostasis | (Lugini et al., 2012) |
| sEVs | NK cells | miR-186 | MYCN AURKATGFBR1TGFBR2 | Inhibit neuroblastoma growth and immune escape | (Neviani et al., 2019) |
| sEVs | NK cells | miR-3607-3p | IL-26 | Inhibited pancreatic cancer progression | (Sun et al., 2020) |
| EVs | IL15-cultured NK cells | — | — | Enhance the anti-tumor effect | (Zhu et al., 2019) |
| sEVs | IL2/IL15-NK cells | DNAM1 | — | Mediate cytotoxicity of tumor | (Di Pace et al., 2020) |
| sEVs | Circulating NK cells | — | — | Exhibit antitumoral activity | (Kang et al., 2021) |
| sEVs | CD4+ T cells | — | — | Inhibit CD8+ T cells responses and anti-tumor immunity | (Zhang et al., 2011) |
| EVs | Activated CD8+ T cells | — | — | Prevent tumor progression | (Seo et al., 2018) |
| sEVs | Activated T cells | PD-1 | — | Attenuate PD-L1-induced immune dysfunction | (Qiu et al., 2021) |
| sEVs | CD45RO-CD8+ T cells | miR-765 | — | Restrict cancer development | (Zhou et al., 2021) |
| NVs | Activated CD8+ T cells | Granzyme B, PD-1, | — | For cancer immunotherapy | (Hong et al., 2021) |
| NVs | Ginseng | — | — | Inhibit melanoma growth | (Cao et al., 2019) |
| NVs | Citrus limon | — | — | Inhibit CML xenograft growth | (Raimondo et al., 2015) |
| NVs | PEGylated asparagus cochinchinensis | — | — | Inhibit tumor growth | (Zhang et al., 2021) |